Bortezomib in Treating Patients With Mantle Cell Lymphoma
Status:
Completed
Trial end date:
2009-12-21
Target enrollment:
Participant gender:
Summary
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary
for cancer cell growth.
PURPOSE: Phase II trial to study the effectiveness of bortezomib in treating patients who
have previously untreated or relapsed mantle cell lymphoma.